drugset / Trial / NCT00763412
Pilot and Feasibility Study for the Treatment of Pre-diabetes in Patients With Cystic Fibrosis
Completed
31 enrolled
Arbelaez, Ana Maria
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · collabNational Institutes of Health (NIH) · collabNovo Nordisk A/S · collabWashington University School of Medicine · collab
RandomizedParallel-groupQuadruple-blindOther
Summary
The purpose of this study is to provide the necessary data and experience to design a larger, full scale clinical trial to determine if a certain medicine (repaglinide), which increases the amount of insulin secreted by the pancreas, can improve the nutritional status and pulmonary function of adolescents and young adults with cystic fibrosis and prediabetes by improving blood glucose control. The investigators are also trying to determine the relationship between systemic inflammatory factors and glucose impairment.
Timeline
- Start
- 2006-11
- Primary completion
- 2013-01
- Completion
- 2013-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Repaglinide | Small molecule | 0.5 mg | Oral |